FRANKLIN LAKES, N.J., April 3, 2023  BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Michelle Quinn has been named executive vice president and general counsel for the company, effective April 1.

Quinn has responsibility for leading the Law Group at BD. She will continue to report to Tom Polen, chairman, CEO and president of BD.

Quinn joined BD in 2019 and prior to her current role served as acting general counsel as well as senior vice president, deputy general counsel, and chief ethics and compliance officer. Before joining BD, she was vice president and general counsel of North America for Sandoz Inc., a division of Novartis, and prior to that served as vice president and associate general counsel at Catalent Pharma Solutions.

"Michelle exemplifies BD's core value of doing what is right, and I look forward to her continued strategic guidance as our general counsel," Polen said. "Michelle's deep experience in leading legal functions in a variety of health care companies has and will continue to benefit BD, our associates, the patients we serve and our shareholders through her focus on advancing the company's business strategies and governance initiatives."

Quinn holds a Juris Doctor from Villanova University and a Bachelor of Arts in Political Science from Colgate University.

About BD

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 77,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo.